Lavipharm SA
ATHEX:LAVI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lavipharm SA
Operating Income
Lavipharm SA
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lavipharm SA
ATHEX:LAVI
|
Operating Income
€6.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Lavipharm SA
Glance View
Lavipharm SA engages in the manufacture and import of pharmaceuticals and veterinary products. The company is headquartered in Athina, Attiki. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. The company is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.
See Also
What is Lavipharm SA's Operating Income?
Operating Income
6.1m
EUR
Based on the financial report for Jun 30, 2025, Lavipharm SA's Operating Income amounts to 6.1m EUR.
What is Lavipharm SA's Operating Income growth rate?
Operating Income CAGR 5Y
2%
Over the last year, the Operating Income growth was -36%. The average annual Operating Income growth rates for Lavipharm SA have been 20% over the past three years , 2% over the past five years .
